NYMXFNymox Pharmaceutical Corp.

About Nymox Pharmaceutical Corp. (NYMXF)

Nymox Pharmaceutical Corp. (NYMXF) is a Biotechnology company headquartered in QUEBEC CANADA, QC, Canada whose shares trade over-the-counter on the OTCQB tier.

Nymox Pharmaceutical Corporation is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer.

Products and services

Former products no longer marketed and sold include an Alzheimer's diagnostic kit, and a tobacco alert kit. Products in development include biopharmaceuticals used to treat various disorders including benign prostatic hyperplasia and prostate cancer.

NYMXF key facts

Ticker symbol

NYMXF

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

QUEBEC CANADA, QC, Canada

Country of incorporation

BS

Year of incorporation

2015

Employees

7

Estimated market cap

$10.40M (as of Apr 16, 2025)

Shares outstanding

94,540,140

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Nymox Pharmaceutical Corp. leadership

• Paul Averback — CEO
• Patrick Arthur Doody — Vice President, General Counsel
• Kathleen Prins — Other

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with N